Trevi Therapeutics, Inc. · NASDAQ:TRVI
Trevi Therapeutics — European Respiratory Society Congress 2026
13 slides from Trevi Therapeutics's conference presentation, Sep 5, 2026
Slide 1: Assessment of Quality of Life using the Leicester Cough Questionnaire from the Phase 2b CORAL Trial
Assessment of Quality of Life using the Leicester Cough Questionnaire from the Phase 2b CORAL Trial: Nalbuphine Extended Release for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis Marlies Wijsenbeek-Lourens 1, Peter Saunders 2, James Casella 3, Philip Molyneaux 4,5 1 Erasmus MC Univers
Slide 2: Conflict of interest disclosure
Conflict of interest disclosure ❑ I have no real or perceived conflicts of interest that relate to this presentation. ❑ I have the following real or perceived conflicts of interest that relate to this presentation: Affiliation / Financial interest Commercial company Grants/research support: The Neth
Slide 3: Background: Chronic Cough in Patients With IPF
Background Chronic Cough in Patients With IPF • Chronic cough affects ~80% of patients with IPF and is associated with reduced QoL • Oral nalbuphine extended release (NAL ER) is a dual acting kappa opioid receptor agonist and mu opioid receptor antagonist that is thought to reduce cough- related neu
Slide 4: Differences in Opioid Receptor Interactions Across Medication Classes Drive Variation in Outcomes
Differences in Opioid Receptor Interactions Across Medication Classes Drive Variation in Therapeutic and Safety Outcomes Partial µ agonist κ agonist Opioid µ agonist κ agonist μ antagonist antagonist Class of medication Fentanyl, morphine, Butorphanol Nalbuphine Naloxone, Examples hydromorphone, Pen
Slide 5: Methods: CORAL Phase 2b Study Design
Methods CORAL Phase 2b Study Design Population • Patients with IPF and a history of chronic cough (≥8 weeks) Primary Efficacy Endpoint (mITT population) Secondary Objectives • Change from baseline in LCQ total score at Week 6 • Relative change from baseline in 24-hour cough • Change from baseline in
Slide 6: Patient Demographics
Patient Demographics Total Characteristic (N = 165)* Age (years), mean (std) 70.1 (7.29) Gender, n (%) Male 118 (71.5%) Female 47 (28.5%) Cough Duration (years), Mean (std) 4.22 (6.60) Mean Dose Group Range of Baseline 24-Hour Cough Frequency (coughs/hour) 24.6 - 31.5 Mean Dose Group Range of Baseli
Slide 7: Objective 24-Hour Cough Frequency
Objective 24-Hour Cough Frequency Primary Endpoint: Relative Change from Baseline at Week 6 Statistically significant reduction in objective cough count from baseline observed across all dose groups * p<0.01 ** p<0.001 *** p<0.0001 NAL ER / nalbuphine ER is an investigational therapy mITT population
Slide 8: Leicester Cough Questionnaire: Total Score
Leicester Cough Questionnaire: Total Score Secondary Endpoint: Absolute Change from Baseline at Week 6 Statistically significant and clinically meaningful improvement in LCQ Total Score at 54 mg BID and 108 mg BID dose groups Change from Baseline in the LCQ Total Score at Week 6 4.00 P<0.05 3.50 3.7
Slide 9: Leicester Cough Questionnaire: Physical, Psychological, and Social Domains
Leicester Cough Questionnaire: Physical, Psychological, and Social Domains Secondary Endpoint: Absolute Change from Baseline at Week 6 Physical (8 items) Psychological (7 items) Social (4 items) • Chest or stomach pains due to coughing • Feel in control of the cough • Interference with job or other
Slide 10: Clinically-Meaningful Responders on LCQ Scale
Clinically-Meaningful Responders on LCQ Scale Secondary Endpoint: Achievement of 1.3 unit change in Total LCQ Score Statistically significant difference in responder rate observed at 54 mg BID and 108 mg BID dose groups BID, twice daily; LCQ, Leicester Cough Questionnaire Nalbuphine ER/NAL ER is an
Slide 11: Summary of Common TEAEs by Preferred Term
Summary of Common (≥ 10% in Total Active Group) TEAEs by Preferred Term Placebo 27 mg BID 54 mg BID 108 mg BID Total Active (N = 40) (N = 42) (N = 43) (N = 40) (N = 125) Preferred Term n (%) n (%) n (%) n (%) n (%) Nausea 2 (5.0) 6 (14.3) 16 (37.2) 20 (50.0) 42 (33.6) Vomiting 0 4 (9.5) 11 (25.6) 11
Slide 12: Conclusions
Conclusions • Treatment with NAL ER resulted in statistically significant dose-related reduction in cough frequency and an overall safety profile consistent with previous studies and drug class • NAL ER 54 mg BID and 108 mg BID significantly improved patient-reported cough-related QoL compared with
Slide 13: Thank you!
Thank you! We would like to thank the study participants, the investigators, and the site staff for their dedication to conducting this trial This trial was sponsored by Trevi Therapeutics
Trevi Therapeutics — European Respiratory Society Congress 2026 on 6ix